Prevalence of aspirin resistance in coronary artery disease among Indian patients

Sibi Narayanan Syamalakumari, Abhilash Kannan, Geethu Gopinathan Nair


Background: Aspirin is one of the most widely consumed drugs in this world. The first report of a possible antithrombotic effect of aspirin appeared in 1953 in the Mississippi Valley Medical Journal. Objective of the study was to determine the prevalence of aspirin resistance among Indian patients with coronary artery disease.

Methods: Patients were prospectively enrolled from all stable cardiac patients presenting to the outpatient wing of Department of Medicine of a tertiary care centre in South Kerala. Duration of study was one year. All patients who were more than 21years old and who had taken 150mg of aspirin for the previous seven days were eligible for enrolment.

Results: Aspirin resistance was found in 9.3% of patients. 17.3% of patients were aspirin semi responder.

Conclusions: There was statistically significant correlation of aspirin resistance with presence of diabetes mellitus, systemic hypertension and dyslipidemia. Cigarette smoking did not show any significant association with aspirin resistance


Aspirin, Aspirin resistance, Coronary artery disease, Dyslipidemia, Platelet aggregation, Platelet rich plasma

Full Text:



Craven LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Mississippi Valley Med J. 1953;75:38-44.

Smith JB, Wills AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971;231:235-7.

Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA. 1975;72:3073-6.

Hamberg M, Svensson J, Samuelsson B. Thromboxanes. A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975;72:2994-8.

Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin – resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-55.

Mehta J, Mehta P, Burger C, Pepine CJ. Platelet aggregation studies in coronary artery disease. Effect of aspirin. Atherosclerosis. 1978;31:169-75.

Grotomeyer KH, Scharafinski HW, Hustedt IW. Two year follow up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients. Thromb Res. 1993;71:397-403.

Muller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D et al. Variable platelet response to low dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thronb Haemost. 1997;78:1003-7.

Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995;11:221-7.

Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, Aspirin or both after myocardial infarction. N Eng J Med. 2002;347:969-74.

Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trial and therapy. Arch Pathol Lab Med. 1994;118:801-4.

Hung J, Lam JY, Lacoste L, Lechacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995;92:2432-6.

Davis JW, Hartman CR, Lewis HD Jr, Shelton L, Eigenberg DA, Hassanein KM, et al. Cigarette smoking induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med. 1985;105:479-83.

Patrono C, Coller B, Dalen JE. Platelet acive drugs: the relationship among dose, effectiveness and side effects. Chest. 1998;114:470S-8S.